Current Hepatitis Reports

, 8:169

Quantitative HBsAg titer as predictor of response to therapy

  • Emilia Hadziyannis
  • Dimitrios Vassilopoulos
  • Stephanos J. Hadziyannis

DOI: 10.1007/s11901-009-0024-8

Cite this article as:
Hadziyannis, E., Vassilopoulos, D. & Hadziyannis, S.J. Curr hepatitis rep (2009) 8: 169. doi:10.1007/s11901-009-0024-8


The expanding availability of different potent antiviral agents for the treatment of chronic hepatitis B (CHB) has created optimism for achieving treatment goals, such as the loss of serum hepatitis B surface antigen (HBsAg), which represents the closest-to-cure outcome of chronic hepatitis B virus infection. Recent studies indicated the potential usefulness of HBsAg quantification during antiviral therapy (especially with interferon-α-based regimens) as a potential predictor of virologic response. This article critically reviews the most recent data regarding the value of measurements of HBsAg concentrations in predicting response in patients with hepatitis B e antigen (HBeAg)-positive and HBeAg-negative CHB treated with different antiviral agents.

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Emilia Hadziyannis
  • Dimitrios Vassilopoulos
  • Stephanos J. Hadziyannis
    • 1
  1. 1.Department of Medicine and HepatologyHenry Dunant HospitalAthensGreece